Gedivumab is under investigation in clinical trial NCT01877785 (A Study of MHAA4549A to Assess Safety And Pharmacokinetics in Healthy Volunteers).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Gedivumab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Gedivumab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Gedivumab. |
| Estrone | Estrone may increase the thrombogenic activities of Gedivumab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Gedivumab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Gedivumab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Gedivumab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Gedivumab. |
| Estriol | Estriol may increase the thrombogenic activities of Gedivumab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Gedivumab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Gedivumab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Gedivumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Gedivumab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Gedivumab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Gedivumab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Gedivumab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Gedivumab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Gedivumab. |
| Equol | Equol may increase the thrombogenic activities of Gedivumab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Gedivumab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Gedivumab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Gedivumab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Gedivumab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Gedivumab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Gedivumab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Gedivumab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Gedivumab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Gedivumab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Gedivumab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Gedivumab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Gedivumab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Gedivumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Gedivumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Gedivumab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Gedivumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Gedivumab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Gedivumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Gedivumab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Gedivumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Gedivumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Gedivumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Gedivumab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Gedivumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Gedivumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Gedivumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Gedivumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Gedivumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Gedivumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Gedivumab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Gedivumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Gedivumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Gedivumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Gedivumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Gedivumab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Gedivumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Gedivumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Gedivumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Gedivumab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Gedivumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Gedivumab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Gedivumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Gedivumab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Gedivumab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Gedivumab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Gedivumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Gedivumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Gedivumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Gedivumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Gedivumab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Gedivumab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Gedivumab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Gedivumab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Gedivumab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Gedivumab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Gedivumab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Gedivumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Gedivumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Gedivumab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Gedivumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Gedivumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Gedivumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Gedivumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Gedivumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Gedivumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Gedivumab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Gedivumab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Gedivumab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Gedivumab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Gedivumab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Gedivumab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Gedivumab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Gedivumab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Gedivumab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Gedivumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Gedivumab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Gedivumab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Gedivumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Gedivumab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Gedivumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Gedivumab. |